Scientists Discover How Cancer Cells Resist Radiation and New Way to Stop Them
Researchers found cancer cells use JAK1 protein to survive radiation therapy, but targeting KIF18A protein can overcome this resistance.
Summary
Scientists discovered how head and neck cancer cells resist radiation therapy through a protein called JAK1. When JAK1 is lost, cancer cells become better at surviving radiation by pausing their cell division cycle longer, giving them time to repair DNA damage. However, researchers found a weakness in this survival strategy. These radiation-resistant cancer cells become vulnerable to drugs that target another protein called KIF18A. When both radiation and KIF18A inhibitors are used together, cancer cells experience fatal stress during cell division and die more effectively than with radiation alone.
Detailed Summary
This breakthrough cancer research reveals why some tumors resist radiation therapy and offers a promising new treatment approach. Scientists studied head and neck squamous cell carcinoma, an aggressive cancer type, to understand mechanisms behind treatment resistance.
Researchers used advanced genetic screening techniques to identify genes that help cancer cells survive radiation. They discovered that loss of JAK1 protein function makes cancer cells more resistant to radiation by allowing them to pause longer during cell division, giving time to repair DNA damage.
The team found that JAK1-deficient cancer cells have prolonged cell cycle arrest and delayed progression to mitotic catastrophe, the process where damaged cells die during division. These cells showed reduced activation of key proteins PLK1 and AURKA, leading to abnormal cell division patterns including tetraploidy.
Crucially, researchers identified a therapeutic vulnerability: radiation-resistant cancer cells become highly sensitive to KIF18A inhibition. The drug sovilnesib, which targets KIF18A, creates fatal mitotic stress when combined with radiation therapy, effectively killing previously resistant cancer cells.
For longevity and health optimization, this research advances precision cancer treatment by identifying biomarkers for therapy selection. Patients with JAK1-deficient tumors might benefit from combination treatments targeting KIF18A alongside radiation. This personalized approach could improve survival rates and reduce treatment toxicity by using targeted therapies more effectively.
The findings also contribute to understanding cellular stress responses and DNA repair mechanisms, knowledge applicable beyond cancer to aging research and cellular health maintenance strategies.
Key Findings
- JAK1 protein loss makes head and neck cancer cells resistant to radiation therapy
- JAK1-deficient cancer cells pause cell division longer, allowing DNA damage repair
- KIF18A inhibitor sovilnesib overcomes radiation resistance in JAK1-deficient tumors
- Combination therapy creates fatal mitotic stress in previously resistant cancer cells
- PLK1 and AURKA protein activation is reduced when JAK1 function is lost
Methodology
Researchers used pooled genetic CRISPR-Cas9 screening on head and neck squamous cell carcinoma cell lines. They employed EdU labeling and live cell imaging to track cell cycle progression and mitotic behavior. The study tested JAK1 knockout effects and KIF18A inhibition using the drug sovilnesib.
Study Limitations
The study focused specifically on head and neck cancer cell lines, so results may not apply to other cancer types. Clinical trials are needed to confirm the safety and efficacy of KIF18A inhibitor combinations in human patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.